Resmed Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Resmed Inc (RMD) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Resmed Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 5,743M vs 19,133M combined for its competitors (23.1% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (+0.4% annualized vs trailing 12 months), vs holding steady (+1.8%) for its tracked peer group.
- Growth: Resmed Inc generated 8.7% revenue growth year over year in Q1 2026, vs 4.6% for its competitors combined.
- Profitability: Its 29.0% net margin compares with 1.8% for the peer group.
- Scale: Resmed Inc ranks #10 of 246 companies by market capitalization in the Medical Equipment & Supplies industry, holding 2.8% of industry market cap.
- Peer revenue share: Resmed Inc accounted for 22.9% of combined revenue among its tracked peer group, up from 22.2% a year earlier.
- Peer differentiation: Revenue per employee of $0.51M compares with $0.30M for the peer group (1.7x).
- Structure: Resmed Inc operates in the following segments: Devices, Masks and Other, Residential Care Software.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
RMD Sales vs. its Competitors, Q1 2026
Resmed Inc reported revenue growth of 8.67 % year on year in Q1 2026, above its competitors' combined revenue growth of 4.63 %.
With a net margin of 29.02 %, Resmed Inc achieved higher profitability than its competitors (1.79 %).
Resmed Inc generated 22.85 % of the combined sales of its peer group, up from 22.19 % a year earlier.
API endpoints for this dataset
Resmed Inc vs. its Competitors, Q1 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Resmed Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Resmed Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Resmed Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (2) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (7) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Resmed Inc's competitor groups requires a Commercial License.
For context: the Medical Equipment & Supplies industry grew revenue 14.4% year over year, combined, vs 8.7% for Resmed Inc. Resmed Inc's share of combined industry revenue moved from 1.30% to 1.24%, a loss of 0.07 percentage points.
Resmed Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Resmed Inc | Yes | Yes | Yes | No |
| Competitors combined (17) | ||||
| High-Confidence Competitors (5) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 75.00 % (6 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
RMD Stock Performance relative to its Competitors
RMD Stock Performance relative to High-Confidence Competitors
RMD Stock Performance relative to Similar-Size Competitors
RMD Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Becton Dickinson And Company | 282.9% | Outperformed |
| 2 | Baxter International Inc | 282.9% | Outperformed |
| 3 | Icu Medical Inc | 282.9% | Outperformed |
| 4 | Profound Medical Corp | 282.9% | Outperformed |
| 5 | Electromed Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Resmed Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Resmed Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Resmed Inc |
33,807.71 | 5,743.16 |
 Becton Dickinson And Company |
59,227.76 | 20,840.00 |
 Koninklijke Philips Nv |
29,635.47 | 20,163.51 |
 Baxter International Inc |
13,733.20 | 11,784.00 |
 Masimo Corp |
9,465.37 | 1,557.00 |
 Icu Medical Inc |
4,497.18 | 2,183.56 |
| SUBTOTAL | 154,878.64 | 67,959.18 |
Sign in to see all competitors of Resmed Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Resmed Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Resmed Inc's Competitors Named by the Company
Competitive relationships identified from Resmed Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Inspire Medical Systems inc | Company report | 85% |
| Koninklijke Philips Nv | Company report | 85% |
| Appyea Inc | Company report | 85% |
| Fisher & Paykel Healthcare Corporation Limited | Company report | 85% |
| Inspira Technologies Oxy B H N Ltd | Company report | 85% |
| BMC Medical Co. Ltd. | Company report | 85% |
| Philips BV | Company report | 85% |
| Inogen Inc | Company report | 85% |
| DeVilbiss Healthcare | Company report | 85% |
| Apex Medical Corporation | Company report | 85% |
| Prosomnus Inc | Company report | 85% |
| Electromed Inc | Company report | 85% |
| Vapotherm Inc | Company report | 85% |
| Vivos Therapeutics Inc | Company report | 85% |
| Invacare Holdings Corporation | Company report | 85% |
| Advanced Oxygen Technologies Inc | Company report | 85% |
| Prolung Inc | Company report | 85% |
| Masimo Corp | Company report | 85% |
| Adapthealth Corp | Company report | 85% |
Company report basis, confidence, active dates and source counts for Resmed Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Resmed Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Resmed Inc | Devices 49.96 % |
| Becton Dickinson And Company | Medical Essentials 34.94 % |
| Baxter International Inc | Medical Products and Therapies 68.60 % |
| Masimo Corp | Health Care 99.95 % |
| Inspire Medical Systems inc | Operating 100.00 % |
| Adapthealth Corp | Sleep Health 52.82 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Resmed Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Resmed Inc | 33,808 | 505,116 | 140,120 |
| Becton Dickinson And Company | 59,228 | 289,444 | 13,069 |
| Koninklijke Philips Nv | 29,635 | 294,706 | 14,823 |
| Baxter International Inc | 13,733 | 314,240 | -19,280 |
| Masimo Corp | 9,465 | 707,727 | 34,682 |
| Icu Medical Inc | 4,497 | 167,966 | 4,641 |
| PEERS TOTAL | 121,071 | 298,295 | 4,371 |
Resmed Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Resmed Inc | Combined Europe Asia and other markets 31.05 % |
| Becton Dickinson And Company | United States 61.88 % |
| Baxter International Inc | Non-US 0.91 % |
| Icu Medical Inc | UNITED STATES 59.62 % |
| Inspire Medical Systems inc | United States 95.54 % |
| Profound Medical Corp | CA 66.91 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Resmed Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 218 companies in Resmed Inc's industry classification, broader than the peer set above. Market cap in millions of $.Resmed Inc ranks #10 of 218 companies by market capitalization in its industry, holding 2.82 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 607, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 164,558 | 13.47 % |
| 2 | Medtronic Plc | 132,095 | 10.81 % |
| 3 | Stryker Corp | 125,732 | 10.29 % |
| 4 | 3m Company | 98,540 | 8.06 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 7 | Becton Dickinson And Company | 1,234 | 5.2% |
| 8 | Alcon inc | 1,234 | 5.2% |
| 9 | Medline Inc | 1,234 | 5.2% |
| 10 | Resmed Inc | 34,431 | 2.82 % |
Market cap and industry share for the rest of Resmed Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-09.
Resmed Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 5 | Boston Scientific Corporation | 64,921 | -56.07 % |
| 6 | Edwards Lifesciences Corporation | 60,480 | 25.18 % |
| 7 | Becton Dickinson And Company | 59,228 | 55.95 % |
| 8 | Alcon inc | 37,284 | 0.32 % |
| 9 | Medline Inc | 1,234 | 12.3% |
| 10 | Resmed Inc | 34,431 | -7.19 % |
| 11 | Dexcom Inc | 1,234 | 12.3% |
| 12 | West Pharmaceutical Services Inc | 1,234 | 12.3% |
| 13 | Steris Plc | 1,234 | 12.3% |
| 14 | Zimmer Biomet Holdings Inc | 1,234 | 12.3% |
| 15 | Carlisle Companies Incorporated | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Resmed Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-09. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Resmed Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (342 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 60.97 % | 46.20 % (avg) | +14.8 pp |
| Operating Margin | 32.96 % | industry median | +27.8 pp |
| EBITDA Margin | 40.74 % | -6.66 % (avg) | +47.4 pp |
| Capital Intensity (Capex / Revenue) | 2.86 % | 7.13 % (avg) | -4.3 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Resmed Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (342 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Equipment & Supplies industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 19.9x | 36.9x | -17.0x |
| EV / EBITDA | 13.1x | 17.8x | -4.7x |
| P/B | 5.0x | 4.6x | +0.4x |
| Return on Equity | 25.50 % | industry aggregate | 10.17 % |
| Return on Invested Capital | 13.72 % | -6.78 % (avg) | 20.50 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Resmed Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 19.61 % | 9.55 % | 33.58 % | 31.60 % | -15.99 % | 8.67 % | 9.57 % | 9.58 % |
| Operating Margin | 24.51 % | 23.24 % | 23.64 % | 19.93 % | 25.43 % | 25.51 % | 31.87 % | 33.90 % |
| Return on Invested Capital | 12.67 % | 11.20 % | 13.10 % | 13.76 % | 12.39 % | 11.04 % | 13.88 % | 13.78 % |
| P/E | 42.3x | 48.9x | 44.3x | 71.5x | 39.8x | 25.4x | 28.4x | 25.3x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Resmed Inc's Strategic Group Map
Resmed Inc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Resmed Inc's trailing-12-month revenue growth of 9.9% and operating margin of 33.0% compares with an average of 10.9% growth and 27.2% margin across its 8 closest peers by combined growth, margin and ROIC -- Resmed Inc sits below that peer average on growth and above it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Resmed Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Resmed Inc falls in the Dog quadrant: relative market share of 0.21x vs its largest competitor, in an industry growing revenue 8.9% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Resmed Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 607 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 2.86 % vs industry average 7.13 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Resmed Inc's dedicated Suppliers and Customers pages, not here.
Resmed Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Resmed Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Resmed Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 27.8 points above the industry median.
- Return on equity 10.2 points above the industry aggregate.
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.21x).
Opportunities
- Trades at a lower P/E than the industry average (19.9x vs 36.9x) despite a higher return on invested capital -- a possible re-rating opportunity.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Resmed Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Resmed Inc | 1.05 | 3.03 | 0.10 |
| Becton Dickinson And Company | 0.10 | 1.00 | 0.73 |
| Koninklijke Philips Nv | 0.37 | 1.32 | 0.73 |
| Baxter International Inc | 0.58 | 1.96 | 0.10 |
| Masimo Corp | 0.45 | 2.48 | 0.63 |
| Icu Medical Inc | - | 2.38 | 0.58 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Resmed Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Resmed Inc | Q3 2026 | +8.7 % | +20.0 % |
| Becton Dickinson And Company | Q2 2026 | +5.4 % | -34.3 % |
| Koninklijke Philips Nv | Q4 2025 | +3.4 % | - |
| Baxter International Inc | Q3 2026 | +8.1 % | - |
| Masimo Corp | Q1 2026 | +8.3 % | - |
| Icu Medical Inc | Q3 2026 | +4.4 % | - |
| PEERS TOTAL | +4.2 % | +16,339.8 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Resmed Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Resmed Inc | Q3 2026 | +5.1 % | +13.4 % |
| Becton Dickinson And Company | Q2 2026 | +7.1 % | -12.8 % |
| Koninklijke Philips Nv | Q4 2025 | +4.6 % | -11.3 % |
| Baxter International Inc | Q3 2026 | +5.1 % | -0.9 % |
| Masimo Corp | Q1 2026 | +10.1 % | +29.3 % |
| Icu Medical Inc | Q3 2026 | -3.1 % | -43.7 % |
Resmed Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Resmed Inc | 18.67% | 21.10% | 25.50% |
| Becton Dickinson And Company | 1.77% | 2.22% | 3.79% |
| Koninklijke Philips Nv | 3.21% | 3.86% | 7.86% |
| Baxter International Inc | - | - | - |
| Masimo Corp | 4.04% | 5.17% | 9.08% |
| Icu Medical Inc | 1.51% | 1.74% | 2.81% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Resmed Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Resmed Inc | 21.49 | 5.89 |
| Becton Dickinson And Company | 65.03 | 2.84 |
| Koninklijke Philips Nv | 33.11 | 1.47 |
| Baxter International Inc | - | 1.17 |
| Masimo Corp | 124.10 | 6.08 |
| Icu Medical Inc | 74.52 | 2.06 |
| PEERS AVERAGE | 61.83 | 2.28 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.